ArticleACS omega2026
Chemosensitizer Effects of Coencapsulation of Curcumin and Cabazitaxel in Nanostructured Lipid Carriers in Glioblastoma Cells.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common primary tumors of the central nervous system and are associated with poor prognosis. Current therapy with Temozolomide shows limited efficacy, highlighting the need for new treatment options. Cabazitaxel (CBZ), a chemotherapeutic agent approved for prostate cancer, has shown efficacy in preclinical glioblastoma models. However, there is a need for strategies to reduce toxicity and enhance delivery. Curcumin (CUR), known for its antitumor, anti-inflammatory, and antioxidant properties, has been investigated as a potential chemosensitizer. Here, we developed and characterized a nanostructured lipid carrier (NLC) for codelivery of CBZ and CUR, evaluating its cytotoxic effect on U87MG GBM cells. The NLCs were optimized using a Box-Behnken design and exhibited a size below 150 nm, low polydispersity, and stability. The NLC-CUR/CBZ showed spherical morphology and low crystallinity that contributed to high encapsulation efficiency of both compounds (>98%). Furthermore, this system exhibited high cellular internalization and cytotoxic activity, reducing the IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.